Articles

Importance of Health Equity in Gynecologic Cancers

In this second installment, Paula will discuss a health equity study investigating the association of neighborhood socioeconomic deprivation in patients with gynecologic cancers. Read More ›

Videos

SIM0270 Monotherapy and in Combination With Everolimus Shows Promise in Advanced Breast Cancer Treatment

By Erica L. Mayer, MD, MPH

SABCS 2024 - Breast Cancer Faculty Commentary

Dr Erica Mayer explains the results of a study utilizing the novel SERD SIM0270, as monotherapy and in combination, in the treatment of patients with estrogen receptor–positive, HER2-negative advanced breast cancer. Read More ›

Videos

Study Demonstrates Elacestrant Benefit Is Maintained Regardless of ESR1 Mutation Levels

By Erica L. Mayer, MD, MPH

SABCS 2024 - Breast Cancer Faculty Commentary

Dr Erica Mayer discusses an analysis of the EMERALD study, which explores the effects of variant allele frequencies on outcomes for patients with advanced breast cancer being treated with elacestrant. Read More ›

Videos

Real-World Outcomes of Elacestrant in Patients With ESR1-Mutated Breast Cancer

By Erica L. Mayer, MD, MPH

SABCS 2024 - Breast Cancer Faculty Commentary

Dr Erica Mayer comments on real-world outcomes for elacestrant derived from the GuardantINFORM database, and describes which patients elacestrant therapy may be best for. Read More ›

Videos

Imlunestrant Shows Promise for Patients With ESR1-Mutated Advanced Breast Cancer

By Erica L. Mayer, MD, MPH

SABCS 2024 - Breast Cancer Faculty Commentary

Dr Erica Mayer discusses the positive results of the EMBER-3 trial, and the impact that imlunestrant will have on the treatment of patients with advanced breast cancer Read More ›

SIM0270 Demonstrates Promising Activity in Advanced Breast Cancer

SABCS 2024 - Breast Cancer

SIM0270, a new monotherapy treatment for advanced breast cancer, shows promising clinical activity and a manageable safety profile in a phase 1 clinical trial. Read More ›

SIM0270 and Everolimus Combination: A Promising Treatment for Advanced Breast Cancer

SABCS 2024 - Breast Cancer

SIM0270, a novel selective estrogen receptor degrader, combined with everolimus shows preliminary efficacy with a high rate of treatment-emergent adverse events at the recommended dose in treating patients with advanced breast cancer. Read More ›

Racial Disparities in Treatment and Outcomes for Hormone Receptor–Positive/HER2-Negative Metastatic Breast Cancer

SABCS 2024 - Breast Cancer

Racial disparities are evident in the treatment and outcomes for patients with hormone receptor–positive/HER2-negative metastatic breast cancer in the United States. Read More ›

Early Detection of Relapse in Early-Stage Breast Cancer: The ZEST Study

SABCS 2024 - Breast Cancer

The ZEST study explored the potential of niraparib in treating early-stage breast cancer patients with detectable ctDNA, paving the way for future research on personalized treatment strategies based on ctDNA detection. Read More ›

Dalpiciclib Shows Continued Benefit in Advanced Breast Cancer Treatment

SABCS 2024 - Breast Cancer

Final analysis of the DAWNA-2 trial confirms the addition of dalpiciclib to endocrine therapy significantly improves progression-free survival in patients with hormone receptor–positive/HER2-negative advanced breast cancer. Read More ›

Articles

Page 9 of 143